



File / dossier : 6.01.07

Date: 2021-04-29

Edocs: 6551918

## **Oral Presentation**

**Written submission from the  
Organization of Canadian Nuclear  
Industries**

## **Exposé oral**

**Mémoire de l'  
Organization of Canadian Nuclear  
Industries**

In the Matter of the

À l'égard de

**BWXT Medical Ltd.**

---

**BWXT Medical Ltd.**

---

Application for a Class IB nuclear substance  
processing facility operating licence

Demande pour un permis d'exploitation d'une  
installation de traitement de substances  
nucléaires de catégorie IB

**Commission Public Hearing**

**Audience publique de la Commission**

**June 9, 2021**

**9 juin 2021**

April 29, 2021

Senior Tribunal Officer, Secretariat  
Email: [cnscc.interventions.ccsn@canada.ca](mailto:cnscc.interventions.ccsn@canada.ca)

**Re Hearing Notice NO: 2021-H-05  
BWXT Medical Ltd. Application for a Class 1B License**

Dear Senior Tribunal Officer

On behalf of the Organization of Canadian Nuclear Industries (OCNI) I would like to support BWXT Medical's application for Class 1B License to undertake nuclear medicine business operations within the medical isotopes portion of its facility in Kanata, Ontario.

BWXT Medical Ltd. is a division of BWXT's Nuclear Power Group segment in Canada who has been a member of OCNI for 35 years. In my capacity as President and CEO of OCNI I have personally observed BWXT Canada's high standards for quality and its commitment to worker and public safety. I am therefore confident that upon receipt of its operating license BWXT Medical will continue to produce the same medical products, previously produced by Nordion, reliably and safely in the same facility while meeting and exceeding all nuclear and health regulatory requirements.

BWXT Medical, headquartered in Kanata, delivers medical isotopes to hospitals radiopharmaceutical companies, and radiopharmacies around the world that conduct or support life-saving medical procedures for patients. The quality of BWXT Medical products is derived from decades of experience of its predecessor company Nordion in the development, manufacture, and delivery of medical isotopes and radiopharmaceuticals. Since the 2018 acquisition of the Nordion medical isotope division, BWXT Medical has expanded its workforce from approximately 120 to approximately 200 skilled professionals who are developing new and innovative products for the medical industry.

BWXT Medical is developing innovative technology to produce Molybdenum-99 (Mo-99) which is currently used in more than 40 million diagnostic imaging procedures annually worldwide to diagnose cancer, coronary artery disease and other adverse medical conditions. Pending approval from FDA and Health Canada, BWXT Medical will provide a stable, reliable, long-term supply of Tc-99m - supporting the growing demand for diagnostics for many years to come. It is therefore important from a worldwide public health perspective that BWXT Medical be granted a Class 1B operating license.

In addition to its demonstrated track record in meeting/exceeding all regulatory requirements, BWXT Medical is committed to communicating and engaging with the Kanata community in a meaningful way through a dedicated public information website where community members can find detailed information about BWXT Medical operations. Community members can also sign up for BWXT Medical's email list to receive regular updates.

**For the reasons cited above, OCNI strongly supports BWXT Medical's Application for Class 1B Operating License for its facility in Kanata Ontario.**

**I would also be pleased to make an oral presentation at CNSC Public Hearing on June 9/10.**

Yours sincerely



Dr. Ron Oberth  
President and CEO